Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes

Wi Sun Ryu, Dawid Schellingerhout, Keun Sik Hong, Sang Wuk Jeong, Beom Joon Kim, Joon Tae Kim, Kyung Bok Lee, Tai Hwan Park, Sang Soon Park, Jong Moo Park, Kyusik Kang, Yong Jin Cho, Hong Kyun Park, Byung Chul Lee, Kyung Ho Yu, Mi Sun Oh, Soo Joo Lee, Jae Guk Kim, Jae Kwan Cha, Dae Hyun KimJun Lee, Moon Ku Han, Man Seok Park, Kang Ho Choi, Matthias Nahrendorf, Juneyoung Lee, Hee Joon Bae, Dong Eog Kim

Research output: Contribution to journalArticlepeer-review

7 Scopus citations

Abstract

Objective: We investigated (1) the associations of pre-stroke aspirin use with thrombus burden, infarct volume, hemorrhagic transformation, early neurological deterioration (END), and functional outcome, and (2) whether stroke subtypes modify these associations in first-ever ischemic stroke. Methods: This multicenter magnetic resonance imaging (MRI)-based study included 5,700 consecutive patients with acute first-ever ischemic stroke, who did not undergo intravenous thrombolysis or endovascular thrombectomy, from May 2011 through February 2014. Propensity score-based augmented inverse probability weighting was performed to estimate adjusted effects of pre-stroke aspirin use. Results: The mean age was 67 years (41% women), and 15.9% (n = 907) were taking aspirin before stroke. Pre-stroke aspirin use (vs nonuse) was significantly related to a reduced infarct volume (by 30%), particularly in large artery atherosclerosis stroke (by 45%). In cardioembolic stroke, pre-stroke aspirin use was associated with a ~50% lower incidence of END (adjusted difference = −5.4%, 95% confidence interval [CI] = −8.9 to −1.9). Thus, pre-stroke aspirin use was associated with ~30% higher likelihood of favorable outcome (3-month modified Rankin Scale score < 3), particularly in large artery atherosclerosis stroke and cardioembolic stroke (adjusted difference = 7.2%, 95% CI = 1.8 to 12.5 and adjusted difference = 6.4%, 95% CI = 1.7 to 11.1, respectively). Pre-stroke aspirin use (vs nonuse) was associated with 85% less frequent cerebral thrombus-related susceptibility vessel sign (SVS) in large artery atherosclerosis stroke (adjusted difference = −1.4%, 95% CI = −2.1 to −0.8, p < 0.001) and was associated with ~40% lower SVS volumes, particularly in cardioembolic stroke (adjusted difference = −0.16 cm3, 95% CI = −0.29 to −0.02, p = 0.03). Moreover, pre-stroke aspirin use was not significantly associated with hemorrhagic transformation (adjusted difference = −1.1%, p = 0.09). Interpretation: Pre-stroke aspirin use associates with improved functional independence in patients with first-ever ischemic large arterial stroke by reducing infarct volume and/or END, likely by decreasing thrombus burden, without increased risk of hemorrhagic transformation. ANN NEUROL 2021;90:763–776.

Original languageEnglish (US)
Pages (from-to)763-776
Number of pages14
JournalAnnals of Neurology
Volume90
Issue number5
DOIs
StatePublished - Nov 2021

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Relation of Pre-Stroke Aspirin Use With Cerebral Infarct Volume and Functional Outcomes'. Together they form a unique fingerprint.

Cite this